Motavizumab - New Biological Therapy for RSV Prevention

Print-Icon
Print

MedImmune, wholly owned by AstraZeneca, has a growing pipeline of products in development for the prevention and treatment of RSV.
 
«Back

Return to Project




Home
New On This Site
Products & Services
Company A-Z
Industry Projects
White Papers
Jobs & Careers
Press Releases
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area


RSS What is RSS
For every phase of your drug development